Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acel ...

November 13, 2024—R3 Vascular Inc. recently announced that the FDA granted investigational device exemption (IDE) approval to initiate the company’s ELITE-BTK pivotal trial of Magnitude, its ...

November 11, 2024—iVascular announced the initiation of OPAL, a first-in-human study of Amber, the company’s embolic liquid ...

For as many as 200 million people around the world affected by peripheral artery disease (PAD), 1 the evolution of endovascular innovations certainly provides a source of optimism. Within 3 decades, ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

Front Line Medical Technologies Inc. COBRA-OS REBOA (large vessel balloon occlusion device; 4-F; 25-mm diameter-balloon; guidewire-free) Distal Intended for temporary occlusion of large vessels ...

Cerenovus PulseRider Aneurysm Neck Bridging Device T shape, Y shape 2.7–3.5, 3.4–4.5 8.6, 10.6 ...

Merit Medical Systems, Inc. Merit Advance Angiographic Needles 18, 19, 20, 21 (smooth and echo-enhanced) 2.5, 4, 7, 9 Merit Medical Systems, Inc. Merit Advance ...

Front Line Medical Technologies Inc. COBRA-OS REBOA (large vessel balloon occlusion device; 4-F; 25-mm-diameter balloon; guidewire-free) Aortic Temporary occlusion of large blood vessels and/or ...

CVRx, Inc. announced recently that the Centers for Medicare and Medicaid Services (CMS) assigned the company’s Barostim p ...

Front Line Medical Technologies Inc. COBRA-OS REBOA (large vessel balloon occlusion device; 4-F; 25-mm-diameter balloon; guidewire-free) Aortic Temporary occlusion of large blood vessels and/or ...

In the LIFE-BTK trial, several initiatives were implemented to facilitate enrollment of diverse populations, ensuring that pati ...